Look up one drug

Reason for Use code 310 As second-line therapy for patients who do not have an adequate intraocular pressure lowering response to monotherapy with ophthalmic beta-blocking agents. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 393 For use as initial therapy in an urgent situation (e.g. patients with a high baseline intraocular pressure) where monotherapy is unlikely to be effective. Coverage limit: LU Authorization Period: Indefinite

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

Apo-Brimonidine-Timop · DIN 02375311 Manufacturer: Apotex Inc.; listing date 2022-12-21 Health Canada: Marketed since 2022-11-09 · brand APO-BRIMONIDINE-TIMOP · ATC S01ED51 TIMOLOL, COMBINATIONS, S01ED51 TIMOLOL, COMBINATIONS · form Solution · route Ophthalmic · ingredients TIMOLOL (TIMOLOL MALEATE) 0.5 %, BRIMONIDINE TARTRATE 0.2 % · company Apotex inc · schedule Prescription

DIN 02375311: Apo-Brimonidine-Timop Raw flags: sec12=Y, sec3=Y Item: 523600115; group id 615; item number 1582; lccId 00156; manufacturer id APX Source form: Oph Sol-10mL Pk; strength: 0.2% & 0.5% Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $23.2900; ministry $23.2900 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02375311 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86073

Interchangeable products

Combigan · DIN 09857298 · $23.2900 Jamp Brimonidine/Timolol · DIN 02531704 · $23.2900

Shortage status: active shortage (reported 2025-12-16, estimated to end 2027-01-08, last updated 2026-09-04); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02375311

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Reason for Use code 310 As second-line therapy for patients who do not have an adequate intraocular pressure lowering response to monotherapy with ophthalmic beta-blocking agents. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 393 For use as initial therapy in an urgent situation (e.g. patients with a high baseline intraocular pressure) where monotherapy is unlikely to be effective. Coverage limit: LU Authorization Period: Indefinite

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

Jamp Brimonidine/Timolol · DIN 02531704 Manufacturer: Jamp Pharma Corporation; listing date 2023-08-31 Health Canada: Marketed since 2023-07-21 · brand JAMP BRIMONIDINE/TIMOLOL · ATC S01ED51 TIMOLOL, COMBINATIONS, S01ED51 TIMOLOL, COMBINATIONS · form Solution · route Ophthalmic · ingredients BRIMONIDINE TARTRATE 0.2 %/W/V, TIMOLOL (TIMOLOL MALEATE) 0.5 %/W/V · company Jamp pharma corporation · schedule Prescription

DIN 02531704: Jamp Brimonidine/Timolol Raw flags: sec12=Y, sec3=Y Item: 523600115; group id 615; item number 1582; lccId 00156; manufacturer id JPC Source form: Oph Sol-10mL Pk; strength: 0.2% & 0.5% Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $23.2900; ministry $23.2900 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02531704 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102081

Interchangeable products

Apo-Brimonidine-Timop · DIN 02375311 · $23.2900 Combigan · DIN 09857298 · $23.2900

Shortage status: active shortage (reported 2026-03-12, estimated to end 2026-07-31, last updated 2026-05-13); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02531704

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Reason for Use code 310 As second-line therapy for patients who do not have an adequate intraocular pressure lowering response to monotherapy with ophthalmic beta-blocking agents. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 393 For use as initial therapy in an urgent situation (e.g. patients with a high baseline intraocular pressure) where monotherapy is unlikely to be effective. Coverage limit: LU Authorization Period: Indefinite

Combigan · DIN 09857298 Manufacturer: Allergan Inc.; listing date 2008-08-28 No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Health Canada record for this brand: DIN 02248347 (Marketed, 2023-12-13) Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=72692

DIN 09857298: Combigan Raw flags: sec12=Y, sec3=Y Item: 523600115; group id 615; item number 1582; lccId 00156; manufacturer id ALL Source form: Oph Sol-10mL Pk; strength: 0.2% & 0.5% Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $46.5800; ministry $23.2900 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=09857298 Health Canada record for this brand: DIN 02248347 (Marketed, 2023-12-13) Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=72692

Interchangeable products

Apo-Brimonidine-Timop · DIN 02375311 · $23.2900 Jamp Brimonidine/Timolol · DIN 02531704 · $23.2900

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=09857298

Shortage record checked 2026-09-13T08:10:21.292534+00:00